Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Cencora Inc stock reached a significant milestone, hitting an all-time high of 315.58 USD. With a market capitalization of $61.62 billion, the healthcare services provider has demonstrated remarkable stability, as InvestingPro data shows the stock typically trades with low volatility. This achievement underscores a remarkable period of growth for the company, as reflected in its impressive 1-year return of 42.55% and a strong year-to-date gain of 40.66%. The stock’s performance has demonstrated resilience and investor confidence, marking a substantial increase in value. According to InvestingPro’s Fair Value analysis, the stock appears slightly undervalued despite trading at a P/E ratio of 32.78. The record high reflects positive market sentiment and favorable business developments, with InvestingPro analysis showing expected net income growth this year. As the company continues to navigate the complexities of the market, this milestone could serve as a catalyst for further investor interest and engagement. Discover 14 additional exclusive ProTips and comprehensive valuation metrics for Cencora Inc by accessing the detailed Pro Research Report, available to InvestingPro subscribers.
In other recent news, Cencora Inc. reported its third-quarter earnings for 2025, surpassing Wall Street expectations. The company achieved an earnings per share of $4, exceeding the forecast of $3.84. Additionally, Cencora’s revenue reached $80.7 billion, surpassing the anticipated $80.31 billion. Despite these positive financial results, the company’s stock experienced a decline, attributed to broader market conditions and potential future challenges. In another development, Wells Fargo raised its price target for Cencora to $354 from $337, maintaining an Overweight rating on the stock. The investment firm highlighted strong core U.S. Healthcare performance as a key factor for this adjustment, although it noted moderately weaker international results. These updates reflect recent developments concerning Cencora’s financial performance and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.